FDA Mediation Watch: Pradaxa (dabigatran etexilate mesylate) Capsules: Special Storage and Handling Requirements
by fdanews on Wednesday, March 30th, 2011 | No Comments
Potential for product breakdown and loss of potency if not dispensed and stored in the original bottle or blister package.
MedWatch Safety Alert RSS Feed
Related posts:
- FDA New Drugs Feed: FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules [03-29-2011] The U.S. Food and Drug Administration (FDA) is alerting...
- FDA Mediation Watch: Irinotecan Hydrochloride Injection: Recall – Fungal Microbial Contaminant Non-sterility of a chemotherapeutic product administered via the intravenous route...
- FDA Mediation Watch: U-Prosta: Undeclared Drug Ingredient Product marketed as dietary supplement contains terazosin, adverse health consequences...
- FDA Mediation Watch: Cook Inc., Single, Double, Triple and Five-Lumen Central Venous Catheter Trays AND Single and Double Lumen PICC Peripheral Inserted Central Venous Catheter Trays: Class I Recall – Leaks in Plunger Luer Detected Leakage and possible loss of sterility, which may lead to...
- FDA Mediation Watch: Terbutaline: Label Change – Warnings Against Use for Treatment of Preterm Labor Potential for serious maternal heart problems and death. MedWatch Safety...